Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas

Abstract

Multidisciplinary treatment for acinar cell carcinoma of the pancreas should be considered due to the rarity of the disease and its lack of high-level therapeutic data. Progress in the molecular analysis of this tumor may improve outcomes through the use of personalized therapy based on underlying tumor mutations.

Curative distal pancreatectomy in patients with acinar cell carcinoma of pancreas diagnosed by endoscopic aspiration via esophago-jejunostomy: A successful case report

“…Characteristics of ACC has been well understood by some systemic review worldwide and the effectiveness of preoperative diagnosis and surgical treatments were clarified at this stage [ [7] , [8] , [9] ]. ACC patients may have non-specific symptoms or laboratory data [ 10 ], and the present case had a discomfort at the site of mass lesion.…”

“…Curative pancreatectomy could be performed less than half of all ACC patients [ [3] , [7] ] and curability and tumor stage were influenced to patient prognosis although the tumor recurrence rate was still high [ 18 ]. In the present case, the problematic issue regarding operation was influences of prior operation and reconstruction procedure and we attempted to avoid injury of jejunal loop and its mesenteric vascularization.…”

“…As a result, node metastasis was not observed by the final histological evaluations and the curative distal pancreatectomy could be successfully undergone. As the adequate adjuvant chemotherapy or its regimen for ACC may not been unproven with enough evidences [ [7] , [9] ], or node metastasis was not observed, the adjuvant chemotherapy has not been given for the present case. The tumor-relapse of this patient was not observed by the careful imaging managements for 12 months at a moment.…”

Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report

“…For metastatic PACC, the chemotherapy protocol of PDAC has been used, which includes gemcitabine, 5-FU, oxaliplatin, CPT-11, and S-1, or their combinations [ 14 – 16 ]. A systematic review by Glazer et al demonstrated that the disease control rate of chemotherapy was 55% and median survival time in metastatic PACC after chemotherapy was 17 months [ 17 ]. However, the efficacies of various chemotherapies have not been studied in controlled, prospective studies, and there are no definitive guidelines for the treatment of metastatic PACC.…”

Pancreatic acinar cell carcinoma—case report and literature review

“…The best therapeutic regimen is comprehensive treatment based on radical resection [ 14 ]. Patients with resectable lesion can benefit from surgical removal.…”